Evaluation of T1N0M0 lung cancer with CT

Staging of non-small cell lung cancer: imaging of intrathoracic disease

This article reviews the contribution of diagnostic imaging to the intrathoracic staging of non-small cell lung cancer. The principle features of the current staging system are discussed along with the relative roles of the various imaging modalities in the evaluation of the primary tumour and metastatic disease. The emerging role of positron emission tomography with fluorodeoxyglucose (FDG-PET) as a clinically useful, potentially cost effective, complementary imaging technique is also reviewed.

Bronchogenic carcinoma: a survey of CT protocols for staging disease

RATIONALE AND OBJECTIVES

To determine whether a standard computed tomographic (CT) protocol is used in the staging of lung cancer.

MATERIALS AND METHODS

A questionnaire was designed to determine what type of CT scanner is used, whether intravenous contrast material is used, how often the abdomen is scanned and at what level, and the section thicknesses used in scanning the chest and abdomen in patients with lung cancer. A total of 1,118 survey forms were mailed to members of the Society of Thoracic Radiology and to all community hospitals in the United States with at least 300 beds.

RESULTS

The authors received 520 responses (47%) to the 1,118 questionnaires mailed. Of these 520 responses, 140 were from society members, 256 were from hospitals with 300-500 beds, and 124 were from hospitals with more than 500 beds. One-half of hospital respondents used helical CT scanners. Significantly more society members used helical CT scanners (P < .001). Intravenous contrast material was used to opacify mediastinal blood vessels at 449 (86%) of 520 hospitals. Intravenous contrast material was used for liver scanning at 363 (82%) of 444 hospitals, but it was used less often at hospitals in the northeast region and by society members than at hospitals in other regions (P < .001). A mixture of section thicknesses was commonly used (252 [48%] of 520 responses) for scanning the chest; a thickness of 8-10 mm was used in scanning the abdomen at most hospitals (348 [78%] of 445 responses).

CONCLUSION

No CT protocol is consistently used for the examination of patients with lung cancer. Use of intravenous contrast material during chest or liver CT also is not uniform.

Distribution of distant metastases from newly diagnosed non-small cell lung cancer

BACKGROUND

The purpose of our study was to determine the incidence and locations of M1 disease at presentation in patients with non-small cell lung cancer to help design appropriate preoperative imaging algorithms.

METHODS

All patients with non-small cell lung cancer seen between 1991 and 1993 were identified, and records were reviewed. For patients with M1 disease, the sites of distant metastases and the methods of diagnosis were recorded.

RESULTS

Of 348 patients identified, 276 (79%) had M0 disease and 72 (21%) had M1 disease. In 40 of 72 patients (56%), M1 disease was detected via chest or abdominal computed tomography (CT). Brain, bone, liver, and adrenal glands were the most common sites of metastatic disease, in decreasing order. Brain metastases often occurred as an isolated finding, although isolated liver metastases were uncommon.

CONCLUSIONS

M1 disease was common at presentation, and was often detectable via chest CT. The incremental yield of abdominal CT over chest CT was very small, and therefore abdominal CT is not an effective method of screening for metastases if chest CT has been performed.

Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma

PURPOSE

To assess the role of positron emission tomographic (PET) imaging with 18-fluoro-2-deoxyglucose (18FDG) in detecting thoracic lymph node metastases in patients with bronchogenic carcinoma.

MATERIALS AND METHODS

Over a 2-year period, any patient presenting to our institution with newly diagnosed bronchogenic carcinoma who was to have thoracic nodes sampled was considered eligible. All PET studies were performed prior to nodal sampling and areas of increased uptake were mapped according to the American Thoracic Society classification. Studies were correlated with CT and pathology. Sensitivity and specificity for predicting nodal metastases was calculated.

RESULTS

Forty-two patients had 62 nodal stations (40 hilar/lobar, 22 mediastinal) sampled. The sensitivity and specificity for hilar/lobar lymph node station metastases using PET imaging was 73% and 76%, respectively. With CT, the sensitivity and specificity were 27% and 86%. The sensitivity and specificity using PET imaging for mediastinal node station metastases was 92% and 100%, respectively, while with CT the figures were 58% and 80%. The sensitivity and specificity for combined thoracic nodal station metastases using PET imaging was 83% and 82%, respectively, while with CT it was 43% and 85%. There was a strong statistical relationship between positive PET imaging and lymph node abnormalities.

CONCLUSIONS

18FDG-PET imaging is accurate in detecting thoracic lymph node metastases in patients with bronchogenic carcinoma. Normal results of PET studies virtually preclude the need for mediastinal nodal sampling prior to surgery, whereas abnormal results of studies most likely represent mediastinal metastases. Treatment can be based on the extent of disease suggested by PET imaging.